Stocktoria
ADAPTIN BIO, INC. APTN
ADAPTIN BIO, INC. (APTN) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| APTN | ADAPTIN BIO, INC. | 3/9 | — | — | — |
| AMGN | AMGEN INC | 6/9 | 0.14 | 25.1 | +10% |
| GILD | GILEAD SCIENCES, INC. | 7/9 | 3.28 | 18.7 | +2.4% |
| BIIB | BIOGEN INC. | 4/9 | — | 24.7 | +2.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
About ADAPTIN BIO, INC.
Adaptin Bio, Inc., a biotechnology company, develops drug delivery technologies to deliver drugs and other compounds directly to target destinations within the body in the United States. It provides Brain Bispecific T-cell Engager platform, a bispecific antibody technology to target and treat intracerebral malignancies, such as gliomas. It develops APTN-101, a proprietary epidermal growth factor receptor variant III to eliminate malignant glioma tumors in a range of aggressive preclinical tumor models. It caters to patients with oncology, CNS, autoimmune, and cardiovascular conditions, as well as healthcare professionals, researchers, and biopharma partners. The company was founded in 2021 and is based in Charlotte, North Carolina.
FAQ
Is APTN financially healthy?
ADAPTIN BIO, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does APTN pay a dividend?
No, ADAPTIN BIO, INC. does not currently pay a dividend.
Is APTN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ADAPTIN BIO, INC.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.